AKT1 and ovarian carcinoma: Liu et al. [48] determined that ATL I can reduce the expression of TLR4/MD-2 complex on the surface of epithelial ovarian cancer SKOV3 EOC cells, inhibit the MyD88/NF-κB signaling pathway, down-regulate NF-κB, Akt, and IDO1 protein expression, and inhibit the secretion of IL-6, TGF-β1, VEGF, and IL-17A, further reduce the level of regulatory T cells, and attenuate the proliferative response and antitumor cytotoxicity of T lymphocytes exposed to tumor cell supernatants.